Prescient Therapeutics to collaborate with largest cancer centre in the US to develop blood cancer treatment
"We believe that OmniCAR is a transformational platform for cellular immunotherapy, and we look forward...
"We believe that OmniCAR is a transformational platform for cellular immunotherapy, and we look forward...
Prescient’s work is being considered a game-changer in advancing CAR-T therapies for cancer treatment and...
Prescient Therapeutics Ltd (ASX:PTX) managing director and CEO Steven Yatomi-Clarke speaks with Proactive’s Elisha Newell about...
Clinical-stage oncology firm Prescient Therapeutics (ASX: PTX) announces a Share Purchase Plan (SPP) to raise AU$8.0 million.
Clinical stage oncology company Prescient Therapeutics to progress its deep pipeline of innovative cancer therapies...
Clinical-stage oncology company developing personalised therapies Prescient Therapeutics (ASX:PTX) has announced a Share Purchase Plan...
We think that it's fair to say that the possibility of finding fantastic multi-year winners...
Prescient Therapeutics (ASX: PTX) has launched a capital raising targeting $8 million to maintain its momentum...
Prescient Therapeutics (PTX) is looking to raise $8 million via a share purchase plan (SPP) to...
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is working towards expanding its next-generation cell immunotherapy program. At the...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.